5 November 2026 Sydney, Australia

Quotation of Attaching Options

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, advises that the Attaching Options issued under its recent capital raise will be quoted on the ASX.

As outlined in Nyrada's Placement announcement of 21 September 2026 and Securities Purchase Plan (SPP) results announcement of 28 October 2026, the Attaching Options issued to non-Director Placement and SPP participants will commence quotation on Thursday, 5 November 2026 under the ticker **NYRO**.

Each Attaching Option is exercisable at AU$0.93 on or before 25 September 2028 and, on exercise, entitles the holder to one Nyrada CHESS Depositary Interest (CDI) and one Piggyback Option (exercisable at AU$1.40 on or before 26 September 2030).

Each Piggyback Option gives the holder the right to receive one (1) CDI upon exercise and payment of the exercise price. Notwithstanding when an Attaching Option is exercised, no Piggyback Options will be granted until the exercise period for the Attaching Options has expired. Piggyback Options will be offered under a separate disclosure document, expected to be issued in or around September 2028.

For further details, please see the Prospectus.

Director participation in the capital raise, on the same terms as the Placement and SPP, remains subject to CDI holder approval at an Extraordinary General Meeting (EGM) expected to be held in February 2027. Subject to that approval, the Director CDIs and Attaching Options will be quoted within 30 calendar days of the EGM.

-ENDS-

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed and a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - https://www.protect-mi.com
- PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9
- FDA IND Feedback - https://bit.ly/4zyu9dZ
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg

Oncology

- Preclinical cardiomyopathy study - https://bit.ly/4yR9BgD
- Preclinical cardiomyopathy pilot study - https://bit.ly/4xJH3Fj
- Preclinical anti-tumour study - https://bit.ly/49rWOa0

Neuroprotection

- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH

Foundations

- US Patent Grant - https://bit.ly/4yUqMyf
- Phase I results - https://bit.ly/3Nt0GzH
- Preclinical mitochondria stabilisation study - https://bit.ly/4yiZUHa
- GLP study results - https://bit.ly/4d8VYkX
- CSANZ Conference Poster - https://bit.ly/4A9ROmf

Corporate

- Latest presentation slides - https://bit.ly/46FM9Xq

About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, Managing Director and CEO on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.